Solvay, Lundbeck shares tumble on news of psychosis drug delay
Shares in Belgium's Solvay and Denmark's Lundbeck tumbled in overnight trading after the two companies announced a delay in the launch of their psychosis drug bifeprunox. Solvay said that it would proceed with a US application for the drug in mid-2006 with its development partner Wyeth, but added that additional late-stage trials would be needed to satisfy European regulators. A European application is now expected in 2008.
- see this press release
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
